{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:55:26Z","timestamp":1794412526932,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00262-023-03550-z","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T05:03:52Z","timestamp":1696655032000},"page":"4161-4168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study"],"prefix":"10.1007","volume":"72","author":[{"given":"Qi","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"issue":"11","key":"3550_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2017.75.7385","volume":"36","author":"AA Forastiere","year":"2018","unstructured":"Forastiere AA, Ismaila N, Lewin JS et al (2018) Use of larynx-preservation strategies in the treatment of laryngeal cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 36(11):1143\u20131169. https:\/\/doi.org\/10.1200\/JCO.2017.75.7385","journal-title":"J Clin Oncol"},{"issue":"3","key":"3550_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijrobp.2015.03.004","volume":"92","author":"S Grover","year":"2015","unstructured":"Grover S, Swisher-McClure S, Mitra N et al (2015) Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys 92(3):594\u2013601. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.03.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"3550_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/cncr.29241","volume":"121","author":"DI Rosenthal","year":"2015","unstructured":"Rosenthal DI, Mohamed AS, Weber RS et al (2015) Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer 121(10):1608\u20131619. https:\/\/doi.org\/10.1002\/cncr.29241","journal-title":"Cancer"},{"key":"3550_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.oraloncology.2018.11.022","volume":"88","author":"DA Silverman","year":"2019","unstructured":"Silverman DA, Puram SV, Rocco JW, Old MO, Kang SY (2019) Salvage laryngectomy following organ-preservation therapy-an evidence-based review. Oral Oncol 88:137\u2013144. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.11.022","journal-title":"Oral Oncol"},{"issue":"8","key":"3550_CR5","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.1994.12.8.1592","volume":"12","author":"MB Spaulding","year":"1994","unstructured":"Spaulding MB, Fischer SG, Wolf GT (1994) Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. the department of veterans affairs cooperative laryngeal cancer study group. J Clin Oncol 12(8):1592\u20131599. https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1592","journal-title":"J Clin Oncol"},{"issue":"22","key":"3550_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091\u20132098. https:\/\/doi.org\/10.1056\/NEJMoa031317","journal-title":"N Engl J Med"},{"issue":"7","key":"3550_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91\u201311: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845\u2013852. https:\/\/doi.org\/10.1200\/JCO.2012.43.6097","journal-title":"J Clin Oncol"},{"issue":"5","key":"3550_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/lary.30279","volume":"133","author":"A Eita","year":"2023","unstructured":"Eita A, Mohamed N, Rybkin A et al (2023) Outcomes for organ preservation with chemoradiation therapy for T4 larynx and hypopharynx cancer. Laryngoscope 133(5):1138\u20131145. https:\/\/doi.org\/10.1002\/lary.30279","journal-title":"Laryngoscope"},{"issue":"Suppl 1","key":"3550_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00405-008-0697-6","volume":"265","author":"A Dietz","year":"2008","unstructured":"Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl 1):S3\u2013S12. https:\/\/doi.org\/10.1007\/s00405-008-0697-6","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"10","key":"3550_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","volume":"29","author":"A Dietz","year":"2018","unstructured":"Dietz A, Wichmann G, Kuhnt T et al (2018) Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 29(10):2105\u20132114. https:\/\/doi.org\/10.1093\/annonc\/mdy332","journal-title":"Ann Oncol"},{"issue":"3","key":"3550_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","volume":"29","author":"X Hu","year":"2021","unstructured":"Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X (2021) Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy. Mol Ther 29(3):908\u2013919. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.032","journal-title":"Mol Ther"},{"key":"3550_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101480","volume":"52","author":"KE Pauken","year":"2021","unstructured":"Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ (2021) Emerging concepts in PD-1 checkpoint biology. Semin Immunol 52:101480. https:\/\/doi.org\/10.1016\/j.smim.2021.101480","journal-title":"Semin Immunol"},{"issue":"10","key":"3550_CR13","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","volume":"28","author":"A Obradovic","year":"2022","unstructured":"Obradovic A, Graves D, Korrer M et al (2022) Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. Clin Cancer Res 28(10):2094\u20132109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3570","journal-title":"Clin Cancer Res"},{"key":"3550_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fonc.2020.00268","volume":"10","author":"VC Kok","year":"2020","unstructured":"Kok VC (2020) Current understanding of the mechanisms underlying immune evasion from PD-1\/PD-L1 immune checkpoint blockade in head and neck cancer. Front Oncol 10:268. https:\/\/doi.org\/10.3389\/fonc.2020.00268","journal-title":"Front Oncol"},{"issue":"19","key":"3550_CR15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10167","key":"3550_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [published correction appears in Lancet. Lancet 393(10167):156\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"issue":"10212","key":"3550_CR17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591","journal-title":"Lancet"},{"issue":"7","key":"3550_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S et al (2022) Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28(7):1345\u20131352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3351","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03550-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T22:03:31Z","timestamp":1701900211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03550-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3550"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03550-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the submission of the manuscript, which has not been published and is not considered for publication elsewhere in whole or part in any language. The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Ethics Committee of Sun Yat-sen University Cancer Center with a waiver of consent documentation (SL-B2020-326\u201303).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}